Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-PRIME: Maternal Immunization With TdaP2gen in Thailand
NCT07621341Phase 4Not yet recruiting
- Sponsor
- Chiang Mai University
- Start
- May 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in pertussis, diphtheria and Tetanus (3 arms), sponsored by Chiang Mai University. Primary endpoints: Maternal anti-PT, anti-FHA, anti-diphtheria toxoid, and anti-tetanus toxoid IgG geometric mean concentrations and seroresponse rates, Cord blood anti-PT, anti-FHA, anti-diphtheria toxoid, and anti-tetanus toxoid IgG geometric mean concentrations and seroresponse rates and 3 more. Planned start May 2026; status: not yet recruiting.
02
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on NCT07621341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621341.